[ 3 / biz / cgl / ck / diy / fa / ic / jp / lit / sci / vr / vt ] [ index / top / reports ] [ become a patron ] [ status ]
2023-11: Warosu is now out of extended maintenance.

/biz/ - Business & Finance

Search:

View post   
>> No.20224268 [View]
File: 174 KB, 354x765, original_225357898.png [View same] [iqdb] [saucenao] [google]
20224268

>>20224204

Who cares lol

Why is a multibillion dollar pharma giant and a 100m smallcap pharma CEO both following some literally who reviewer?

>> No.20112702 [View]
File: 174 KB, 354x765, original_224383467.png [View same] [iqdb] [saucenao] [google]
20112702

>2020
>he didn't just buy KTOV

https://stocktwits.com/symbol/KTOV

>latest PR

https://www.sec.gov/Archives/edgar/data/1614744/000121390020016497/ea123760ex99-1_kitovpharma.htm

Debt free biopharma under $1 with a drug going to bring millions royalty revenue and two more drugs that are potential cancer fighting blockbusters.. what is there to lose?

>> No.20108495 [View]
File: 174 KB, 354x765, original_224383467.png [View same] [iqdb] [saucenao] [google]
20108495

>>20108429

Its trash? Lets look at the preclinicals..

Keytruda brings Merck 15 billion a year

Keytruda effectiveness : 40%
Keytruda effectiveness w/ NT219: 80%

Now read this highlighted quote.

Did I mention consensi revenues or that this company is debt free????? This isn't even touching on CM-24 collab with Bristol Myers

No brainer

Navigation
View posts[+24][+48][+96]